| The use of nasal calcitonin in the treatment of post-traumatic algodystrophy. | |
| | |
MedLine Citation:
|
PMID: 1863827 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Calcitonin is widely used in the treatment of algodystrophy but a major disadvantage is the need for its parenteral administration. For this reason, we evaluated the effect of 400 iu of nasal calcitonin in the treatment of post-traumatic algodystrophy in a prospective randomized double-blind study. We found no demonstrable effect on the clinical or skeletal progression of the disorder using sensitive methods of measuring the response to treatment. There was, however, a small but significant hypocalcaemic response in the treatment group despite no change in the other indices of bone turnover. Possible reasons for this lack of clinical and skeletal effect are discussed. |
| | |
Authors:
|
D R Bickerstaff; J A Kanis |
Related Documents
:
|
17165277 - Montelukast with desloratadine or levocetirizine for the treatment of persistent allerg... 19766297 - Recommendations for appropriate sublingual immunotherapy clinical trials. 3578927 - Pharmacologic treatment of adverse reactions to foods: comparison of different protocols. 10795647 - Cost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionat... 8522147 - Impact of the interaction of depression and physical illness on a psychiatric unit's le... 3721047 - Lumbar epidural analgesia in hypertensive patients during labour. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: British journal of rheumatology Volume: 30 ISSN: 0263-7103 ISO Abbreviation: Br. J. Rheumatol. Publication Date: 1991 Aug |
Date Detail:
|
Created Date: 1991-09-06 Completed Date: 1991-09-06 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8302415 Medline TA: Br J Rheumatol Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 291-4 Citation Subset: AIM; IM |
Affiliation:
|
Department of Human Metabolism and Clinical Biochemistry, Sheffield. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Intranasal Bone Density / drug effects Calcitonin / administration & dosage*, therapeutic use Calcium / blood Fractures, Bone / complications* Humans Prospective Studies Radionuclide Imaging Radius / injuries* Reflex Sympathetic Dystrophy / drug therapy*, etiology, physiopathology |
| Chemical | |
Reg. No./Substance:
|
7440-70-2/Calcium; 9007-12-9/Calcitonin |
| Comments/Corrections | |
Comment In:
|
Br J Rheumatol. 1992 Aug;31(8):567-9
[PMID:
1643458
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Which patients see a rheumatologist? SWRACR (South Western Regional Advisory Committee on Rheumatolo...
Next Document: Plasma levels of interleukin-1-alpha in rheumatoid arthritis.